James Shin
Stock Analyst at Deutsche Bank
(0)
# 4647
Out of 5,218 analysts
19
Total ratings
0.00%
Success rate
-17.10%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Eli Lilly | Maintains: Buy | 1025 1015 | 789.07 | 28.63% | 4 | Nov 4, 2024 | |
Amgen | Reiterates: Hold | 310 305 | 270.45 | 12.78% | 2 | Aug 7, 2024 | |
Incyte | Maintains: Hold | 55 60 | 68.61 | -12.55% | 2 | Aug 1, 2024 | |
Bristol-Myers Squibb | Maintains: Hold | 53 45 | 55.73 | -19.25% | 2 | Jul 23, 2024 | |
Legend Biotech | Initiates Coverage On: Buy | 60 | 35.19 | 70.5% | 1 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Hold | 75 | 91.85 | -18.35% | 1 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Hold | 150 | 173.5 | -13.54% | 1 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Hold | 800 | 730.7 | 9.48% | 1 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 115 | 102.09 | 12.65% | 1 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 25 | n/a | n/a | 1 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 10 | 2.48 | 303.23% | 1 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 12 | 2.11 | 468.72% | 1 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 80 70 | 2.13 | 3186.38% | 1 | Dec 12, 2022 |